FDA Feedback Streamlines AEON’s Biosimilar Pathway for ABP-450
Event summary
- FDA feedback suggests AEON’s head-to-head studies for ABP-450 may be submitted as supportive evidence.
- AEON plans to submit an IND for a CMAP pharmacodynamic study in Q4 2026.
- FDA indicates traditional comparative efficacy studies may not be necessary if analytical and pharmacodynamic evidence is sufficient.
- AEON aims to leverage existing comparative human evidence from Daewoong Pharmaceutical studies.
- Company expects to return to FDA in 2027 with an integrated evidence package.
The big picture
AEON’s strategic shift aligns with the FDA’s growing reliance on analytical and pharmacodynamic evidence over traditional clinical efficacy studies, potentially reducing development time and costs. The $3.0 billion U.S. therapeutic neurotoxin market presents a significant opportunity for biosimilar entry, with AEON positioning ABP-450 as a direct competitor to BOTOX®. The company’s ability to leverage existing evidence and streamline its development pathway could accelerate its market entry and competitive positioning.
What we're watching
- Regulatory Efficiency
- Whether AEON can successfully navigate the FDA’s evolving biosimilar framework to avoid a standalone comparative efficacy study.
- Clinical Evidence
- The pace at which AEON completes the scientific bridging work to support previously conducted comparative studies.
- Market Entry
- How AEON’s streamlined development path will impact its timeline for full-label U.S. market entry for ABP-450.